🔹 Revenue: $2.44B (Est. $2.35B) 🟢; UP +21% YoY
🔹 EPS : $2.19 (Est. $1.93) 🟢; UP +23% YoY
Non-GAAP FY25 Guidance:
🔸 Worldwide da Vinci Procedure Growth: ~15.5% to 17%
🔸 Gross Margin: 66%–67%; includes ~1% tariff impact
🔸 OpEx Growth: 10%–14%
Q2 Segment:
🔹 Instruments & Accessories Revenue: $1.47B; UP +18% YoY
🔹 Systems Revenue: $575M; UP +28% YoY
🔹 395 da Vinci Surgical Systems Placed (vs. 341 YoY); includes 180 da Vinci 5 systems (vs. 70 YoY)
🔹 Installed Base: 10,488 systems; UP +14% YoY
🔹 Worldwide da Vinci Procedures: UP +17% YoY
Other Metrics
🔹 Net Income: $798M; UP +24% YoY
🔹 Income from Operations: $947M; UP +26% YoY
🔹 Cash, Equivalents & Investments: $9.53B; UP $431M QoQ
🔹 GAAP Operating Income: $743M; UP +31% YoY
🔹 Share-Based Compensation: $200M (included in GAAP Ops Income)
CEO Commentary
🔸 “We’re pleased with our solid performance this quarter, highlighted by continued customer adoption of our newer and existing platforms, including da Vinci 5.” — CEO Dave Rosa
🔸 “We are committed to advancing care and helping our customers provide better patient outcomes, better patient and care team experiences, broadening access to care and decreasing the total cost of care.”
